Data from EMC - Curated by Toby Galbraith - Last updated 11 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

Visit Fluid Management


Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism


Related Content

More information

Category Value
Agency product number EMEA/H/C/002396
Orphan designation No
Date First Approved 24-02-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Zambon S.p.A.
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions